EUVIMEDEUVIMED entdecken
Crossref

Antiseizure Effects of Mirtazapine in a Rat Model of Status Epilepticus Via Cannabinoid Receptor Modulation

Ali Vafaei, Mohammad Amin Manavi, Samaneh Toutounchian, Maedeh Mohaghegh, Razieh Mohammad Jafari, Mohammad Amin Kharaghani, Ahmad Reza Dehpour

Neurochemical Research · 2025-12 · 50 (6)

DOI: 10.1007/s11064-025-04584-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurochemical Research, online erschienen am 22.10.2025. Verfasst von Ali Vafaei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Mirtazapine, Anticonvulsants, Status Epilepticus, Receptors, Cannabinoid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Iran National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Status epilepticus (SE) is a severe neurological condition with high morbidity and mortality rates. Despite the availability of treatments, many cases remain refractory to standard therapies. In this study we investigated the possible anticonvulsant effects of mirtazapine in SE-induced rats, and further examined the underlying mechanisms contributing to its observed neuroprotective properties. Male Wistar rats were subjected to SE and pre-treated with different doses of mirtazapine (3, 10, 30, 50 mg/kg). Seizure severity using Racine's scale and latency of first seizure were assessed. The involvement of cannabinoid receptors was examined using AM-630, a CB2 antagonist (0.5 mg/kg). Diazepam (1 mg/kg), a GABAA positive allosteric modulator, was co-administered with mirtazapine to assess potential involvement of GABA receptors in mirtazapine's effects. The effects of KATP channel modulation were studied using glibenclamide (3 mg/kg), a KATP channel blocker. Additionally, CB1 receptor and indoleamine-2,3-dioxygenase (IDO) expression levels were measured using western blotting. Also, effects of mirtazapine were assessed when administered after SE induction, both alone (3 and 30 mg/kg) and in combination with diazepam (1 mg/kg). Pre-treatment with mirtazapine at doses of 30 and 50 mg/kg significantly reduced seizure severity and increased the latency to the first seizure, indicating a dose-dependent anticonvulsant effect. The anticonvulsant effects were mediated through the activation of CB1 and CB2 receptors, as evidenced by inhibition of these effects by sub-effective dose of AM-630 and upregulation of CB1 receptor expression following mirtazapine treatment. Co-administration of sub-effective doses of diazepam and mirtazapine significantly increased the latency to seizures but did not reduce the SE severity score. Additionally, sub-effective dose of glibenclamide inhibited only the mirtazapine's effects in increasing the latency to seizures but not its reducing of seizure severity. IDO expression remained unchanged, suggesting that the kynurenine pathway may not play a significant role in mirtazapine's anticonvulsant effects in SE. Of note, Mirtazapine either alone or in combination with sub-effective doses of diazepam, did not affect seizures when administrated after SE induction. This study shows that only pre-treatment with mirtazapine can effectively prevent SE primarily through the activation of CB1 and CB2 cannabinoid receptors. Further studies, including clinical trials, are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MirtazapineAnticonvulsantsStatus EpilepticusReceptors, CannabinoidAnimalsMaleRats, WistarRatsDisease Models, AnimalDose-Response Relationship, DrugDiazepamReceptor, Cannabinoid, CB1

Stichwörter der Autor:innen

Cannabinoid receptorsGABAergic systemKATP channelsKynurenine pathwayMirtazapineStatus epilepticus

Substanzen

MirtazapineAnticonvulsantsDiazepamReceptor, Cannabinoid, CB1Receptors, Cannabinoid

Autor:innen und Institutionen

  • Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. Dehpour@yahoo.com.
  • Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Dehpour@yahoo.com.

Förderung

  • Iran National Science Foundation

Zitieren

APA

Vafaei, A., Manavi, M. A., Toutounchian, S., Mohaghegh, M., Jafari, R. M., Kharaghani, M. A., & Dehpour, A. R. (2025). Antiseizure Effects of Mirtazapine in a Rat Model of Status Epilepticus Via Cannabinoid Receptor Modulation. Neurochemical Research, 50(6). https://doi.org/10.1007/s11064-025-04584-8

Vancouver

Vafaei A, Manavi MA, Toutounchian S, Mohaghegh M, Jafari RM, Kharaghani MA, et al. Antiseizure Effects of Mirtazapine in a Rat Model of Status Epilepticus Via Cannabinoid Receptor Modulation. Neurochemical Research. 2025;50(6). doi:10.1007/s11064-025-04584-8

BibTeX
@article{Vafaei2025,
  author = {Vafaei, Ali and Manavi, Mohammad Amin and Toutounchian, Samaneh and Mohaghegh, Maedeh and Jafari, Razieh Mohammad and Kharaghani, Mohammad Amin and Dehpour, Ahmad Reza},
  title = {Antiseizure Effects of Mirtazapine in a Rat Model of Status Epilepticus Via Cannabinoid Receptor Modulation},
  journal = {Neurochemical Research},
  year = {2025},
  volume = {50},
  number = {6},
  doi = {10.1007/s11064-025-04584-8}
}
Kostenlos starten →